Literature DB >> 22332441

Compliance with eye care in glaucoma patients with comorbid depression.

Guy A Weiss1, Yakov Goldich, Elisha Bartov, Zvia Burgansky-Eliash.   

Abstract

BACKGROUND: Comorbid depression may play an important role in non-compliance with medical treatment among patients with chronic illnesses. Glaucoma is a potentially blinding chronic disease requiring life-long commitment to medical therapy. Failure to adhere to anti-glaucoma treatment may lead to disease progression and visual loss.
OBJECTIVES: To assess the prevalence of depressive symptoms in glaucoma patients and the association between these symptoms and non-compliance with anti-glaucoma therapy.
METHODS: In this cross-sectional observational study, compliance with pharmacotherapy was assessed with the Morisky Medication Adherence questionnaire (eight items). Screening for depression was performed by means of the CES-D (Center for Epidemiologic Studies Depression scale). The association between depression and compliance rates was analyzed.
RESULTS: The study group comprised 76 glaucoma patients; 19.7% of the subjects were classified as non-compliant (Morisky cutoff 10) and 21.1% suffered from depression (CES-D cutoff > or = 16). We found a similar level of non-compliance when comparing depressed with non-depressed glaucoma patients. However, a correlation was observed between the level of depression and the level of non-compliance (P = 0.04).
CONCLUSIONS: Our study revealed a similar rate of depression in glaucoma patients and the general israeli population. The presence of depression was not associated with the presence of non-compliance, yet the level of depression was associated with the level of non-compliance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22332441

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


  4 in total

1.  Overcoming Barriers to Eye Care: Patient Response to a Medical Social Worker in a Glaucoma Service.

Authors:  Scott J Fudemberg; Dilru C Amarasekera; Marlee H Silverstein; Kathryn M Linder; Paul Heffner; Lisa A Hark; Michael Waisbourd
Journal:  J Community Health       Date:  2016-08

2.  Melanopsin-expressing retinal ganglion cell loss and behavioral analysis in the Thy1-CFP-DBA/2J mouse model of glaucoma.

Authors:  Qi Zhang; Helen Vuong; Xin Huang; YanLing Wang; Nicholas C Brecha; MingLiang Pu; Jie Gao
Journal:  Sci China Life Sci       Date:  2013-06-01       Impact factor: 6.038

3.  A Randomized Trial to Improve Adherence to Follow-up Eye Examinations Among People With Glaucoma.

Authors:  Benjamin E Leiby; Sarah E Hegarty; Tingting Zhan; Jonathan S Myers; L Jay Katz; Julia A Haller; Michael Waisbourd; Christine Burns; Meskerem Divers; Jeanne Molineaux; Jeffrey Henderer; Charles Brodowski; Lisa A Hark
Journal:  Prev Chronic Dis       Date:  2021-05-20       Impact factor: 2.830

4.  Cost of glaucoma treatment in a developing country over a 5-year period.

Authors:  Gabriel Lazcano-Gomez; María de Los Angeles Ramos-Cadena; Margarita Torres-Tamayo; Alejandra Hernandez de Oteyza; Mauricio Turati-Acosta; Jesús Jimenez-Román
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.